Cytisinicline Awaits FDA Decision: First New Smoking-Cessation Drug in 20 Years

Cytisinicline could become the first new FDA-approved smoking-cessation pharmacotherapy in two decades when its June 20, 2026 PDUFA date arrives. Two phase 3 trials, distinctive short-course dosing, and questions about its place beside varenicline are front of mind.

April 25, 2026 · 4 min read

Why Cytisinicline Is in the News Right Now

Cytisinicline is approaching a regulatory inflection point that primary care has been waiting on for years. The FDA accepted Achieve Life Sciences’ new drug application in September 2025 and set a Prescription Drug User Fee Act target action date of June 20, 2026.

If approved, it would be the first new prescription smoking-cessation drug to clear the FDA in nearly 20 years. The current toolkit — varenicline (a generic since 2021), bupropion sustained release, and nicotine replacement therapy — has not seen a novel mechanism added since varenicline arrived in 2006.

The agency has already granted cytisinicline Breakthrough Therapy designation for the separate, expanding problem of e-cigarette and vaping cessation, signaling regulatory interest beyond the cigarette indication now under review.

The Background

Cytisinicline is a synthetic-quality pharmaceutical formulation of cytisine, a plant alkaloid extracted from Laburnum anagyroides. It is a partial agonist at the α4β2 nicotinic acetylcholine receptor — the same target varenicline (Chantix) acts on — and it has been used as an over-the-counter or low-cost cessation aid in Eastern Europe for decades under the brand Tabex.

The mechanism reduces nicotine craving and blunts the reinforcing effect of smoking, mirroring varenicline’s pharmacology. The clinical question for U.S. regulators has been whether modern, fixed-schedule dosing and contemporary trial design produce results that justify approval — and whether tolerability differs meaningfully from varenicline, whose label history included a now-removed boxed warning for neuropsychiatric effects.

The Evidence Behind Cytisinicline

The application rests on the ORCA (Ongoing Research of Cytisinicline for Addiction) program — two phase 3 trials totaling more than 1,600 randomized participants — plus an open-label long-term safety study (ORCA-OL).

ORCA-2 (Rigotti et al., JAMA 2023): randomized, double-blind, placebo-controlled trial of cytisinicline 3 mg three times daily plus behavioral support, with 6- and 12-week treatment arms. The drug significantly increased biochemically verified abstinence versus placebo.
ORCA-3 (Rigotti et al., JAMA Internal Medicine 2025): replication trial of 792 adults across 20 U.S. sites. For the 12-week regimen, abstinence during weeks 9–12 was 30.3% with cytisinicline vs 9.4% with placebo (odds ratio 4.4; 95% CI 2.6–7.3; P<0.001). For the 6-week regimen, weeks 3–6 abstinence was 14.8% vs 6.0% (OR 2.9; 95% CI 1.5–5.6; P<0.001).
Sustained abstinence through week 24: 20.5% vs 4.2% in the 12-week arm and 6.8% vs 1.1% in the 6-week arm.
Tolerability: The most common adverse events across the program were insomnia, abnormal dreams, headache, and nausea — with nausea rates the company has emphasized as lower than those historically seen with varenicline.

Number needed to treat estimates from ORCA-3 work out to roughly 5 patients to produce one additional 12-week abstainer over placebo — a competitive figure relative to existing pharmacotherapy.

Where Cytisinicline Sits Versus Varenicline

The unresolved question is comparative: head-to-head data against varenicline are limited. A 2014 New Zealand trial (Walker et al., NEJM) found 25 days of cytisine non-inferior to 12 weeks of varenicline, but used an older dosing schedule and a different population.

“People tend to think of smoking cessation medications as interchangeable.” — Frank Leone, MD, MS, Director of Comprehensive Smoking Treatment Programs, University of Pennsylvania (paraphrased remarks indicate they are not interchangeable in his view)

Tobacco-treatment specialists generally see cytisinicline as a complementary option rather than a replacement for varenicline. The case in favor: a potentially better tolerability profile, a shorter standard course (6 or 12 weeks), and an alternative for patients who declined or failed varenicline. The case against: meta-analyses pegging varenicline at a relative risk of approximately 2.27 versus placebo for sustained abstinence remain the established benchmark, and direct comparative data with the modern cytisinicline regimen are still sparse.

The Practical Question for Clinicians

For internists and family physicians, the practical work begins before any FDA decision. Roughly 28 million U.S. adults still smoke cigarettes, and quit-attempt rates are far higher than treatment uptake — fewer than one in three smokers who try to quit use evidence-based pharmacotherapy.

If approved, cytisinicline is unlikely to displace generic varenicline as the default first-line option, but it will plausibly become the preferred choice for patients with prior varenicline-related nausea, those wanting a shorter course, or patients who are wary of the (now-rescinded) neuropsychiatric warnings still anchored in their memory.

Coverage and pricing will determine real-world adoption. Generic varenicline is cheap; cytisinicline’s launch price has not been disclosed, and payer formulary placement could meaningfully shape prescribing patterns.

What to Watch For

The June 20, 2026 PDUFA decision on cytisinicline — and whether the approved label includes both 6-week and 12-week regimens or specifies one
FDA action on a separate cytisinicline indication for e-cigarette and vaping cessation, supported by the ORCA-V1 phase 2 trial
ORCA-OL long-term safety data, particularly in patients with cardiovascular and respiratory comorbidities
Updated guidance from the U.S. Preventive Services Task Force and the American Thoracic Society on first-line tobacco-cessation pharmacotherapy
Launch pricing relative to generic varenicline and payer formulary placement decisions

Sources

Achieve Life Sciences. FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation. Press release, September 3, 2025. Achieve Life Sciences NDA Acceptance Announcement (September 2025)
Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. JAMA Internal Medicine, 2025. Rigotti et al., JAMA Internal Medicine — ORCA-3 Trial (DOI)
Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA, 2023;330:152–160. Rigotti et al., JAMA 2023 — ORCA-2 Trial
HCPLive. Q2 2026 Preview: 6 FDA Decisions to Watch. April 2026. HCPLive — Q2 2026 FDA Decision Preview
CHEST Physician. ORCA-3 Replicates Strong Tobacco Cessation Results for Cytisinicline. August 2025. CHEST Physician — ORCA-3 Coverage with Expert Commentary
European Medical Journal Respiratory. Cytisinicline Proves Potent and Safe for Quitting Smoking. May 2025. EMJ Respiratory — ORCA-3 Results Summary
Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. Cochrane Review — Nicotine Receptor Partial Agonists
Achieve Life Sciences. Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program. November 6, 2025. Achieve Life Sciences Q3 2025 Update